Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2004 1
2007 1
2011 2
2012 1
2013 1
2014 2
2015 3
2016 3
2018 1
2022 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study.
Kühn T, Banys-Paluchowski M, Ditsch N, Stickeler E, Hauptmann M, Schroth J, Karadeniz Cakmak G, Hahn M, Thill M, Reimer T, Fröhlich S, Schmidt E, Wihlfahrt K, Berger T, Basali T, Ruf F, Rief A, Lux MP, Kolberg HC, Rubio IT, Gasparri ML, Kontos M, Bonci EA, Niinikoski L, Murawa D, Pinto D, Peintinger F, Schlichting E, Nina H, Valiyeva Qanimat H, Vanhoeij M, Rebaza LP, Aktas Sezen B, Jursik K, Kadayaprath G, Dostalek L, Kothari A, Perhavec A, Ivanov T, Zippel D, Thongvitokomarn S, Gurleyik MG, Watermann D, Porpiglia M, Lebeau A, Di Micco R, Gentilini OD, de Boniface J, Hartmann S; AXSANA Study Group. Kühn T, et al. Br J Surg. 2025 Sep 2;112(9):znaf180. doi: 10.1093/bjs/znaf180. Br J Surg. 2025. PMID: 40966675
Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655).
Hartmann S, Banys-Paluchowski M, Berger T, Ditsch N, Stickeler E, de Boniface J, Gentilini OD, Schroth J, Karadeniz Cakmak G, Rubio IT, Gasparri ML, Kontos M, Bonci EA, Niinikoski L, Murawa D, Kadayaprath G, Pinto D, Peintinger F, Schlichting E, Dostalek L, Nina H, Valiyeva H, Vanhoeij M, Perhavec A, Zippel D, Rebaza LP, Thongvitokomarn S, Fröhlich S, Ruf F, Rief A, Wihlfahrt K, Basali T, Thill M, Lux MP, Loibl S, Kolberg HC, Blohmer JU, Hahn M, Gurleyik MG, Porpiglia M, Gunay S, Zetterlund L, Kuehn T; AXSANA Study Group. Hartmann S, et al. Eur J Surg Oncol. 2025 Sep;51(9):110253. doi: 10.1016/j.ejso.2025.110253. Epub 2025 Jun 25. Eur J Surg Oncol. 2025. PMID: 40587927 Free article.
Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study.
Kerkmann A, Schinke C, Dordevic A, Kern J, Bangemann N, Finck J, Blohmer JU, Ruprecht K, Göpfert JC, Otto C, Materne B, Endres M, Boehmerle W, Huehnchen P. Kerkmann A, et al. Among authors: bangemann n. Oncologist. 2025 Feb 6;30(2):oyae268. doi: 10.1093/oncolo/oyae268. Oncologist. 2025. PMID: 39403794 Free PMC article.
Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy.
Huehnchen P, Schinke C, Bangemann N, Dordevic AD, Kern J, Maierhof SK, Hew L, Nolte L, Körtvelyessy P, Göpfert JC, Ruprecht K, Somps CJ, Blohmer JU, Sehouli J, Endres M, Boehmerle W. Huehnchen P, et al. Among authors: bangemann n. JCI Insight. 2022 Mar 22;7(6):e154395. doi: 10.1172/jci.insight.154395. JCI Insight. 2022. PMID: 35133982 Free PMC article.
Feasibility and Possible Effects of Mindful Walking and Moderate Walking in Breast Cancer Survivors: A Randomized Controlled Pilot Study With a Nested Qualitative Study Part.
Schröder ML, Stöckigt B, Binting S, Tissen-Diabaté T, Bangemann N, Goerling U, Kröz M, Blohmer JU, Ortiz M, Brinkhaus B. Schröder ML, et al. Among authors: bangemann n. Integr Cancer Ther. 2022 Jan-Dec;21:15347354211066067. doi: 10.1177/15347354211066067. Integr Cancer Ther. 2022. PMID: 35045736 Free PMC article. Clinical Trial.
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, Harbeck N. Gluz O, et al. Among authors: bangemann n. J Natl Cancer Inst. 2018 Jun 1;110(6):628-637. doi: 10.1093/jnci/djx258. J Natl Cancer Inst. 2018. PMID: 29228315 Clinical Trial.
Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial - Protocol of a multicenter, randomized, double-blind, placebo- controlled proof-of-concept phase-2 clinical trial.
Huehnchen P, Bangemann N, Lischewski S, Märschenz S, Paul F, Schmitz-Hübsch T, Blohmer JU, Eberhardt C, Rauch G, Flöel A, Adam S, Schwenkenbecher P, Meinhold-Heerlein I, Hoffmann O, Ziemssen T, Endres M, Boehmerle W. Huehnchen P, et al. Among authors: bangemann n. Front Med (Lausanne). 2022 Aug 11;9:967964. doi: 10.3389/fmed.2022.967964. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36035422 Free PMC article.
20 results